TNF and psoriasis vulgaris: Twelve weeks of TNF-α inhibitor therapy (adalimumab) in adults with moderate-to-severe plaque psoriasis was associated with a clinically meaningful improvement (PASI, BSA, DLQI) and a consistent reduction in TEWL across all sampled regions (elbow, lower leg, abdomen, back, scalp), suggesting a recovery of the epidermal barrier integrity at lesional sites.